Harnessing the therapeutic power of cannabinoids
We want to help people living with debilitating conditions by developing non-addictive pain medications to reduce the reliance on opioids.
Our Science
OCT has a range of compounds in drug development, including proprietary cannabinoid derivatives, phytocannabinoids and completely new chemical entities (NCEs) that target the endocannabinoid system.
Meet the Team
With experience across pharmaceutical operations, R&D, intellectual property, law and finance, OCT’s team has a track record of commercial and clinical excellence and a history of over 20 regulatory approvals for new medicines in the US and the EU. Together, our team is passionate about delivering breakthrough therapies for debilitating conditions.
Recent News
Follow our journey from early-stage discovery work to clinical trials as we aim to harness the therapeutic power of cannabinoids to help people living with debilitating conditions.
